Kanglin Biotechnology

Focus: Kanglin Biotechnology is a China-based biotech firm founded in 2021 specializing in AAV gene therapy and stem cell platforms for serious diseases including beta-thalassemia. The company is early-stage with minimal public commercial footprint.

Gene Therapy Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Kanglin Biotechnology

AI assessmentNot Hiring

No open roles listed right now. Follow Kanglin Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

KL003 Cell Injection Drug Product

Transfusion-dependent Beta-Thalassemia

Phase 1/2

Clinical Trials (1)

NCT06280378Β-Thalassemia Treatment with KL003 Cell Injection

Phase 1/2

Help build intelligence for Kanglin Biotechnology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge AAV and stem cell modalities in high-unmet-need indications like transfusion-dependent beta-thalassemia
Ground-floor opportunity at a founded-2021 biotech with potential for equity upside before major clinical/commercial milestones
Position in China's expanding biotech ecosystem with potential to bridge Western drug development standards

Watch Out For

No active job postings and zero published data suggest minimal current hiring or operational transparency—difficult to assess true size and capability
Only one Phase 1/2 program in pipeline with no Phase 3 or marketed products; high clinical and commercial risk with long timeline to revenue
Zero disclosed funding, revenue, cash position, or financial trajectory—material uncertainty around runway and long-term viability

Generated by Claude from Kanglin Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2021

Portfolio: 1 clinical trial

Top TAs: Hematology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Hematology

1 pipeline

Marketed

Pipeline